Moreover, the downregulation of SAFB2 in PDAC cells suggests that it may exert tumor-suppressive effects by inhibiting the Wnt/β-Catenin pathway, pointing to potential novel therapeutic avenues for PDAC. The gene discussed is SAFB2; the disease is neoplasm.